Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 9:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dermatitis, Atopic Clear all
Completed Not applicable Interventional

A Study of an Eczema Spot Treatment in Providing Eczema Symptoms Relief and Lasting Itch Relief to Affected Skin Area

NCT05226143
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Gel Cream
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 22, 2026, 9:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sebum Collection and Skin Barrier Function Analysis

NCT03112876
View directory record Official record
Conditions
Smoking, Acne, Atopic Dermatitis, Aging
Interventions
Skin Surface Lipid Collection and Skin Barrier Function
Other
Lead sponsor
University of California, Davis
Other
Eligibility
12 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 22, 2026, 9:42 PM EDT
Completed Phase 3 Interventional

This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)

NCT05608343
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Difamilast, Placebo
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
2 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Sep 22, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT02277743
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Placebo (for Dupilumab)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
45
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Sep 22, 2026, 9:42 PM EDT
Terminated Phase 2 Interventional Results available

A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT03831191
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
LY3375880, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
14
States / cities
Fountain Valley, California • Los Angeles, California • Northridge, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Sep 22, 2026, 9:42 PM EDT
Completed No phase listed Observational

Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis

NCT04287608
View directory record Official record
Conditions
Conjunctivitis, Atopic Dermatitis
Interventions
dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Irvine, California • Palo Alto, California • Pasadena, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Sep 22, 2026, 9:42 PM EDT
Not listed No phase listed Observational

A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions

NCT05084417
View directory record Official record
Conditions
Atopic Dermatitis, Dermatology, Vitiligo, Alopecia Areata, Hidradenitis Suppurativa, Psoriasis
Interventions
N/A This is an observational study
Other
Lead sponsor
OM1, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Sep 22, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis

NCT03750643
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
LY3454738, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
19
States / cities
Anniston, Alabama • North Little Rock, Arkansas • Rogers, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Sep 22, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

NCT03706040
View directory record Official record
Conditions
Dermatitis
Interventions
Placebo, Risankizumab
Biological
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Sep 22, 2026, 9:42 PM EDT
Terminated Not applicable Interventional

Evaluating the Effect of Bathing Additives in Atopic Dermatitis

NCT04001855
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Dilute vinegar (acetic acid), Dilute bleach
Other
Lead sponsor
University of Arizona
Other
Eligibility
5 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Sep 22, 2026, 9:42 PM EDT
Completed Phase 1Phase 2 Interventional

A Study to Determine the Safety, Tolerability and Efficacy of KP-413 in Subjects With Atopic Dermatitis(AD)

NCT00932074
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
KP-413 Ointment
Drug
Lead sponsor
Kaken Pharmaceutical
Industry
Eligibility
18 Years to 64 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Clinton Twp., Michigan • Portland, Oregon • Austin, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Sep 22, 2026, 9:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

NCT05436535
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide, Hydrocortisone, Vanicream- Active, Vanicream- Experienced Dupilumab
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older
Enrollment
433 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 22, 2026, 9:42 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

NCT05732454
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Dermatitis, Unspecified, Eczema, Eczema, Atopic
Interventions
etrasimod, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
44
States / cities
Fountain Valley, California • Laguna Hills, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 22, 2026, 9:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema

NCT02357940
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
Experimental Product
Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
6 Months and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
St. Petersburg, Florida • Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Sep 22, 2026, 9:42 PM EDT
Completed No phase listed Observational

Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis

NCT00379678
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 22, 2026, 9:42 PM EDT
Active, not recruiting No phase listed Observational

10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus

NCT00568997
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 22, 2026, 9:42 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
1,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
82
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 22, 2026, 9:42 PM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone

NCT04154033
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Dermatitis
Interventions
Naltrexone, Placebo Cream
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Sep 22, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic Dermatitis

NCT02068352
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
OPA-15406, Vehicle ointment
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
10 Years to 70 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 22, 2026, 9:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index

NCT00879944
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
Blood pressure, Height, Weight, BMI, Waist Circumference
Other
Lead sponsor
Northwestern University
Other
Eligibility
5 Years to 17 Years
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
9
States / cities
San Diego, California • San Francisco, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 22, 2026, 9:42 PM EDT
Recruiting Phase 2 Interventional

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis

NCT07660835
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
6 Months to 23 Months
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 22, 2026, 9:42 PM EDT
Completed Phase 2 Interventional

Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis

NCT06309355
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
YR001 ointment, Placebo
Drug · Other
Lead sponsor
Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Boynton Beach, Florida • Hollywood, Florida • Weston, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 22, 2026, 9:42 PM EDT
Active, not recruiting Phase 2 Interventional

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

NCT07277660
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Galvokimig, Placebo
Biological · Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
20
States / cities
Oceanside, California • Santa Monica, California • Boca Raton, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 22, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis

NCT02347176
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, Tralokinumab Dose 1, Tralokinumab Dose 2, Tralokinumab Dose 3
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
24
States / cities
Phoenix, Arizona • Rogers, Arkansas • Fremont, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 22, 2026, 9:42 PM EDT